Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Blood

Topics

Medicine

Cancer Oncology

Internal Medicine

Hematology

Molecular Biology

Show all topics

DOI

10.1182/blood-2024-207842